CINECA IRIS Institutional Research Information System

LA MOTTA, CONCETTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.408
EU - Europa 7.309
AS - Asia 6.965
SA - Sud America 988
AF - Africa 314
OC - Oceania 33
Continente sconosciuto - Info sul continente non disponibili 1
Totale 31.018
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.986
IT - Italia 2.936
SG - Singapore 2.136
CN - Cina 2.054
SE - Svezia 1.439
HK - Hong Kong 1.152
BR - Brasile 834
DE - Germania 692
BG - Bulgaria 490
TR - Turchia 442
VN - Vietnam 421
GB - Regno Unito 379
CA - Canada 344
AT - Austria 271
RU - Federazione Russa 246
IN - India 193
FI - Finlandia 192
FR - Francia 162
UA - Ucraina 162
KR - Corea 108
CI - Costa d'Avorio 99
JP - Giappone 95
NG - Nigeria 70
NL - Olanda 64
CH - Svizzera 57
BD - Bangladesh 55
PK - Pakistan 48
MX - Messico 47
PL - Polonia 47
BE - Belgio 40
IQ - Iraq 37
AR - Argentina 36
SA - Arabia Saudita 35
ID - Indonesia 33
AU - Australia 30
CO - Colombia 28
VE - Venezuela 28
ZA - Sudafrica 28
MA - Marocco 26
ES - Italia 25
SN - Senegal 22
UZ - Uzbekistan 22
EG - Egitto 17
IE - Irlanda 17
EC - Ecuador 16
CZ - Repubblica Ceca 15
MY - Malesia 15
GR - Grecia 14
KE - Kenya 14
PE - Perù 14
AZ - Azerbaigian 13
JO - Giordania 13
IR - Iran 12
DZ - Algeria 11
KZ - Kazakistan 11
LT - Lituania 11
UY - Uruguay 11
CL - Cile 9
DK - Danimarca 9
PY - Paraguay 9
AE - Emirati Arabi Uniti 8
AL - Albania 8
TW - Taiwan 8
NO - Norvegia 7
JM - Giamaica 6
OM - Oman 6
PH - Filippine 6
IL - Israele 5
LB - Libano 5
PS - Palestinian Territory 5
TH - Thailandia 5
TN - Tunisia 5
HN - Honduras 4
PA - Panama 4
PT - Portogallo 4
RS - Serbia 4
AO - Angola 3
BJ - Benin 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
NZ - Nuova Zelanda 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
BN - Brunei Darussalam 2
BO - Bolivia 2
CR - Costa Rica 2
CY - Cipro 2
GA - Gabon 2
GE - Georgia 2
HR - Croazia 2
KH - Cambogia 2
LC - Santa Lucia 2
LK - Sri Lanka 2
LY - Libia 2
MD - Moldavia 2
ME - Montenegro 2
MK - Macedonia 2
NI - Nicaragua 2
RO - Romania 2
SO - Somalia 2
Totale 30.987
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.634
Ashburn 1.502
Ann Arbor 1.361
Houston 1.225
Singapore 1.169
Hong Kong 1.141
Fairfield 1.065
Chandler 939
Serra 883
Santa Clara 818
Dallas 809
Milan 557
Sofia 489
Beijing 480
Seattle 454
Shanghai 447
Wilmington 409
Cambridge 356
New York 351
Izmir 308
Ottawa 267
Boardman 258
Los Angeles 248
Princeton 230
Jacksonville 210
Vienna 199
Lawrence 192
Dong Ket 168
Hefei 168
Nanjing 163
Medford 158
London 154
Rome 117
Des Moines 116
Seoul 103
Frankfurt am Main 100
Istanbul 100
Abidjan 99
Dearborn 89
Munich 88
Rho 85
Buffalo 76
Redondo Beach 73
São Paulo 73
Florence 69
Lagos 68
Council Bluffs 65
Tokyo 65
Bremen 62
Chicago 62
Pisa 59
Redwood City 56
Lucca 52
Boulder 51
San Diego 51
Bern 49
Columbus 49
Nanchang 48
The Dalles 48
Ho Chi Minh City 47
Düsseldorf 44
Brussels 40
Shenyang 39
Fuzhou 37
Warsaw 37
Jüchen 36
Kunming 36
Pune 34
Hanoi 32
Hebei 32
Ogden 31
Falls Church 30
Marseille 30
Toronto 30
Belo Horizonte 29
San Francisco 29
Rio de Janeiro 27
San Jose 27
Washington 26
Phoenix 24
Guangzhou 23
Nuremberg 23
Changsha 22
Dakar 22
Turku 21
Chennai 20
Jakarta 19
Nürnberg 19
Tashkent 19
Auburn Hills 18
Baghdad 18
Cascina 18
New Delhi 18
Quanzhou 18
Tianjin 18
Denver 17
Norwalk 17
Dhaka 16
Jinan 16
Riyadh 16
Totale 21.860
Salva come PNG Salva come JPEG
Nome #
Derivati isoindolici come attivatori di AMPK 504
1,2-Benzisothiazole Derivatives Bearing 4-, 5-, or 6-Alkyl/arylcarboxamide Moieties Inhibit Carbonic Anhydrase Isoform IX (CAIX) and Cell Proliferation under Hypoxic Conditions 383
A new class of tyrosine kinase inhibitors, “pyrazolo[3,4-d]pyrimidinic”compounds, has antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer 335
Preparation of isoindoline derivatives for use as AMPK activators 317
Benzofuroxane Derivatives as Multi Effective Agents for the Treatment of Cardiovascular Diabetic Complications. Synthesis, Functional Evaluation, and Molecular Modeling Studies 266
Soyasaponins from Zolfino bean as aldose reductase differential inhibitors 264
Exploiting the Pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors, 257
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo 228
Derivati benzofuranici come attivatori di AMPK 226
Acid Derivatives of Pyrazolo[1,5-a]pyrimidine as Aldose Reductase Differential Inhibitors 226
[1,2,4]Triazino[4,3-a]benzimidazole Acetic Acid Derivatives: a New Class of Selective Aldose Reductase Inhibitors 223
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo 222
N-(aroyl)-N-(arylmethyloxy)-α-alanines: selective inhibitors of aldose reductase 221
Deepening the Topology of the Translocator Protein Binding Site by Novel N,N-Dialkyl-2-arylindol-3-ylglyoxylamides 219
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer. 214
Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo 211
[1,2,4]Triazino[4,3-a]benzimidazole Acetic Acid Derivatives: A New Class of Selective Aldose Reductase Inhibitors 209
CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 209
How Reliable Are Current Docking Approaches for Structure-based Drug Design? Lessons from Aldose Reductase 207
Functional Studies in the Year of Pulses: the case of Zolfino landraces (Phaesolus vulgaris L.) 206
3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: Tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands 205
Hemp (Cannabis sativa L.) flour: an active ingredient for the formulation of nutritious, flavorful and affordable foods. 204
3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: A New Class of Selective A1 Adenosine Receptor Antagonists 198
Synthesis and investigation of polyhydroxylated pyrrolidine derivatives as novel chemotypes showing dual activity as glucosidase and aldose reductase inhibitors 198
Sulfonamides incorporating heteropolycyclic scaffolds show potent inhibitory action against carbonic anhydrase isoforms I, II, IX and XII 198
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo 197
Identification of Anxiolytic/Nonsedative Agents among Indol-3-ylglyoxylamides Acting as Functionally Selective Agonists at the γ-Aminobutyric Acid-A (GABAA) α2 Benzodiazepine Receptor 196
Evidence for a Novel Binding Site Conformer of Aldose Reductase in Ligand-Bound State 191
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors 191
Medicinal chemistry of indolylglyoxylamide TSPO high affinity ligands with anxiolytic-like effects 189
Structure-Based Optimization of Tyrosine Kinase Inhibitor CLM3. Design, Synthesis, Functional Evaluation, and Molecular Modeling Studies. 189
Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro 188
5-Amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a Versatile Scaffold to Obtain Potent and Selective A3 Adenosine Receptor Antagonists 186
2-(Benzimidazol-2-yl)quinoxalines: A Novel Class of selective Antagonists at Human A1 and A3 Adenosine Receptors Designed by 3D Database Searching 186
Allosteric Modulators for Adenosine Receptors: An Alternative to the Orthosteric Ligands 185
Pyrido[1,2-a]pyrimidin-4-one derivatives as a novel class of selective aldose reductase inhibitors exhibiting antioxidant activity 183
Benzothiopyranoindole-Based Antiproliferative Agents: Synthesis, Cytotoxicity, Nucleic Acids Interaction, and Topoisomerases Inhibition Properties. 183
Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications 183
Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2 183
Synthesis of a Novel Purine-Containing Heterocyclic Ring System: 8,10-Dimethylindolo[2',3':5,6][1,2,4]triazino[4,3-f]purine-9,11(8H,10H,13H)dione 182
Phenylpyrazolo[1,5-a]quinazolin-5(4H)-one: a suitable scaffold for the development of non-camptothecin Topoisomerase I (Top1) inhibitors 182
Refinement of Structure-activity Relationships of the Triazinobenzimidazole A1AR Antagonists 181
Benzo[d]isothiazoles and Matrix Metalloproteinases. Searching for Novel and Selective Inhibitors of MMP9 181
Pursuing Aldose Reductase Inhibitors through in Situ Cross-Docking and Similarity-Based Virtual Screening 178
A Series of COX-2 Inhibitors Endowed with NO-Releasing Properties: Synthesis, Biological Evaluation, and Docking Analysis 178
Studies in search for selective ligands for GABAA/BzR receptor subtypes: synthesis and biological evaluation of 4'-modified N-(benzyl)indol-3-ylglyoxylamides 177
Synthesis of novel 1-aryl[1]benzoxepino[5,4-c]pyrazole and [1]benzoxepino[5,4-d]pyrimidine derivatives 176
Complexing the Marine Sesquiterpene Euplotin C by Means of Cyclodextrin-Based Nanosponges: A Preliminary Investigation 175
Medicinal chemistry of indolylglyoxylamide GABAA/BzR high affinity ligands: identification of novel anxiolytic/non sedative agents 175
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A(2B) adenosine receptor antagonists 174
Synthesis of Purinobenzodiazepine and Purinobenzotriazocine derivatives, two new heterocyclic ring systems. 173
“Synthesis and antiproliferative evaluation of new substituted Benzothiopyrano[4,3-c] condensed ring systems” 172
Novel N(2)-Substituted Pyrazolo[3,4-d]pyrimidine Adenosine A(3) Receptor Antagonists: Inhibition of A(3)-Mediated Human Glioblastoma Cell Proliferation (dagger) 172
Novel, Highly Potent Aldose Reductase Inhibitors:Cyano(2-oxo-2,3-dihydroindol-3-yl)acetic Acid Derivatives 172
Novel Pyrazolo[3,4-d]pyrimidine Derivatives as ATP-competitive Inhibitors of the Epidermal Growth Factor Receptor Protein Tyrosine Kinase 171
Synthesis and functional evaluation of novel aldose reductase inhibitors bearing a spirobenzopyran scaffold 171
Quinazolinone-based rhodanine-3-acetic acids as potent aldose reductase inhibitors: Synthesis, functional evaluation and molecular modeling study 171
Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs 171
AMPK Activators as Novel Drug Candidates for the Treatment of Inflammatory Bowel Diseases 170
Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer 170
Novel Potent and Selective Human Adenosine A3 Receptor Antagonists Containing the Pyrazolo[3,4-d]pyrimidine Ring System. Synthesis and Biological Evaluation 169
3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: A Novel Template for the Design of Highly Selective A(2B) Adenosine Receptor Antagonists. 169
A New Approach to Control the Enigmatic Activity of Aldose Reductase 168
Synthesis of novel pyrido[3',2':5,6]thiopyrano[3,2-b]indol-5(6H)-ones and 6H-pyrido[3',2':5,6]thiopyrano[4,3-b]quinolines,two new heterocyclic systems. 167
A 2,3-diphenylpyrido[1,2-a] pyrimidin-4-one derivative inhibits specific angiogenic factors induced by TNF-α 165
Effects of the new aldose reductase inhibitor benzofuroxane derivative bf-5m on high glucose induced prolongation of cardiac qt interval and increase of coronary perfusion pressure 165
Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation 163
A1 adenosine receptor antagonists, 3-aryl[1,2,4]triazino[4,3-a]benzimidazol-4-(10H)-ones (ATBIs) and N-alkyl and N-acyl-(7-substituted-2-phenylimidazo[1,2-a][1,3,5]triazin-4-yl)amines (ITAs): different recognition of bovine and human binding sites 161
Novel quinazolinone-based 2,4-thiazolidinedione-3-acetic acid derivatives as potent aldose reductase inhibitors 161
Antiproliferative and proapoptotic activity of CLM3, a novel multiple tyrosine kinase inhibitor, alone and in combination with SN-38 on endothelial and cancer cells 160
Preparation of benzofuran derivatives for use as AMPK activators 160
Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview 158
Synthesis and biological activity of 1,4-dihydrobenzothiopyrano[4,3-c]pyrazole derivatives, novel pro-apoptotic mitochondrial targeted agents 158
Novel N-substituted indol-3-ylglyoxylamides probing the LDi and L1L2 lipophilic regions of the benzodiazepine receptor site in search for subtype-selective ligands 158
Tertiary amides with a five-membered heteroaromatic ring as new probes for the translocator protein 155
Aldose reductase inhibitors: 2013-present 155
Non-nucleoside inhibitors of human adenosine kinase: synthesis, molecular modeling, and biological studies 154
Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model 154
Spirohydantoin Derivatives of Thiopyrano[2,3-b]pyridin-4(4H)-one as Potent in Vitro and in Vivo Aldose Reductase Inhibitors 153
Derivatives of 4-Amino-6-hydroxy-2-mercaptopyrimidine as Novel, Potent, and Selective A3 Adenosine Receptor Antagonists 153
The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors 152
Nuovi derivati acidi acetici quali potenti inibitori dell’Aldoso Reduttasi 151
Synthesis and Biological Evaluation of Pyrido[1,2-d]pyrimidin-4-one Derivatives as Novel Aldose Reductase Inhibitors Exhibiting Antioxidant Activity 151
Pyrazolo[3,4,-d]pyrimidine-4-one Derivatives as Novel and Potent Inhibitors of Adenosine Deaminase 151
Synthesis of New Heterocyclic Ring Systems via [1,3,5]Triazino[1,2-a]benzimidazole Derivatives 151
Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders 151
Naphtho[1,2-d]isothiazole Acetic Acid Derivatives as a Novel Class of Selective Aldose Reductase Inhibitors 150
Small Molecules Containing the Benzo[d]isotiazole Ring System as Novel ATP-Competitive Inhibitors of Epidermal Growth Factor Receptor protein Tyrosine Kinase 149
Geometrically Constrained Derivatives of Indolylglyoxylamides as Ligands Binding the GABAA/BzR Complex. 148
Microwave-assisted Suzuki Coupling in Aqueous Media: a Useful Tool for the Synthesis of 3-Arylindazole Derivatives 146
Novel Aldose Reductase Acetic acid Inhibitors Bearing a Five Membered heterocyclic core 146
Novel treatments for anaplastic thyroid carcinoma 146
Oxy-imino saccharidic derivatives as a new structural class of aldose reductase inhibitors endowed with anti-oxidant activity 146
Derivati spiroidantoinici del Tiopirano[2,3-b]piridin-4(4H)-one quali potenti inibitori dell’aldoso reduttasi 145
Computational Studies of Epidermal Growth Factor Receptor for Docking Reliability, Three-Dimensional Quantitative Structure-Activity Relationship Analysis, and Virtual Screening Studies 145
Sampling protein motion and solvent effect during ligand binding. 144
Antineoplastic Activity of Pazopanib in Anaplastic Thyroid Cancer in Primary Culture 143
Novel Antitumoral Pyrazolopyrimidines Based on Inhibition of Protein Tyrosine Kinase 143
ANTI-ISCHEMIC ACTIVITY OF AN ANTIOXIDANT ALDOSE REDUCTASE INHIBITOR ON DIABETIC AND NON-DIABETIC RAT HEARTS 143
Nuova tipologia di inibitori dell'enzima aldoso reduttasi 143
Totale 18.602
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.722
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.722
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.214 0 0 0 0 0 87 138 183 173 162 98 373
2021/20222.579 61 171 117 205 448 315 63 133 114 69 174 709
2022/20233.392 471 572 256 303 376 433 67 230 466 21 151 46
2023/20242.302 288 258 279 180 327 430 87 47 32 66 69 239
2024/20256.883 62 264 98 424 743 702 517 359 613 871 677 1.553
2025/20264.366 513 899 945 673 762 574 0 0 0 0 0 0
Totale 31.561